ATE309236T1 - Epothilonderivate - Google Patents

Epothilonderivate

Info

Publication number: ATE309236T1
Authority: AT; Austria
Prior art keywords: epothilone derivatives; epothilone; derivatives
Prior art date: 1997-07-08

Application number

AT98930300T

Other languages

English (en)

Inventor

Gregory D Vite

Robert M Borzilleri

Soong-Hoon Kim

James A Johnson

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-08

Filing date

1998-06-16

Publication date

2005-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26729990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE309236(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-16 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2005-11-15 Application granted granted Critical

2005-11-15 Publication of ATE309236T1 publication Critical patent/ATE309236T1/de

Links

150000003883 epothilone derivatives Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)

AT98930300T 1997-07-08 1998-06-16 Epothilonderivate ATE309236T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5195197P	1997-07-08	1997-07-08
US6752497P	1997-12-04	1997-12-04
PCT/US1998/012550 WO1999002514A2 (en)	1997-07-08	1998-06-16	Epothilone derivatives

Publications (1)

Publication Number	Publication Date
ATE309236T1 true ATE309236T1 (de)	2005-11-15

Family

ID=26729990

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT04021059T ATE426598T1 (de)	1997-07-08	1998-06-16	Epothilonderivate
AT98930300T ATE309236T1 (de)	1997-07-08	1998-06-16	Epothilonderivate

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT04021059T ATE426598T1 (de)	1997-07-08	1998-06-16	Epothilonderivate

Country Status (32)

Country	Link
US (10)	US6605599B1 (de)
EP (4)	EP1531153A1 (de)
JP (2)	JP4090514B2 (de)
KR (1)	KR100569041B1 (de)
CN (1)	CN100384834C (de)
AR (1)	AR013358A1 (de)
AT (2)	ATE426598T1 (de)
AU (1)	AU731497B2 (de)
BG (1)	BG64952B1 (de)
BR (1)	BRPI9810555A8 (de)
CA (1)	CA2296012C (de)
CO (1)	CO4940501A1 (de)
CZ (1)	CZ297904B6 (de)
DE (2)	DE69840693D1 (de)
DK (1)	DK1019389T3 (de)
EE (1)	EE04566B1 (de)
EG (1)	EG24464A (de)
ES (2)	ES2322807T3 (de)
GE (1)	GEP20032897B (de)
HU (1)	HU227444B1 (de)
ID (1)	ID23771A (de)
IL (1)	IL133613A (de)
LV (1)	LV12569B (de)
MY (1)	MY124151A (de)
NO (1)	NO322494B1 (de)
NZ (1)	NZ501198A (de)
PE (1)	PE104599A1 (de)
PL (1)	PL197404B1 (de)
RO (1)	RO120340B1 (de)
TR (1)	TR200000065T2 (de)
TW (1)	TW562802B (de)
WO (1)	WO1999002514A2 (de)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5969145A (en) *	1996-08-30	1999-10-19	Novartis Ag	Process for the production of epothilones and intermediate products within the process
ES2312695T3 (es) *	1996-11-18	2009-03-01	Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf)	Epotilones e y f.
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6660758B1 (en) *	1996-12-13	2003-12-09	The Scripps Research Institute	Epothilone analogs
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6365749B1 (en) *	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en)	1998-02-25	2001-10-16	Novartis Ag	Cancer treatment with epothilones
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) *	1998-04-21	2002-12-24	Bristol-Myers Squibb Company	2,3-olefinic epothilone derivatives
US6399638B1 (en) *	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
DE19826988A1 (de)	1998-06-18	1999-12-23	Biotechnolog Forschung Gmbh	Epothilon-Nebenkomponenten
WO2000031247A2 (en)	1998-11-20	2000-06-02	Kosan Biosciences, Inc.	Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en)	1998-11-20	2002-06-25	Kosan Biosciences, Inc.	Myxococcus host cells for the production of epothilones
PT1140944E (pt)	1998-12-22	2004-01-30	Novartis Pharma Gmbh	Derivados de epotilona e sua utilizacao como agentes antitumorais
US6780620B1 (en) *	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
HK1044946A1 (zh) *	1999-02-11	2002-11-08	舍林股份公司	依泊昔酮衍生物、其製備方法及藥物用途
EP1169038B9 (de)	1999-04-15	2013-07-10	Bristol-Myers Squibb Company	Cyclische protein-tyrosinkinasehemmer
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
US7125893B1 (en)	1999-04-30	2006-10-24	Schering Ag	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
DE10020899A1 (de) *	2000-04-20	2001-10-25	Schering Ag	9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
US6489314B1 (en)	2001-04-03	2002-12-03	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
WO2001092255A2 (en) *	2000-05-26	2001-12-06	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
UA75365C2 (en) *	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
IL155306A0 (en)	2000-10-13	2003-11-23	Univ Mississippi	Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
ES2304240T3 (es)	2001-01-25	2008-10-01	Bristol-Myers Squibb Company	Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
EE200300323A (et) *	2001-01-25	2003-10-15	Bristol-Myers Squibb Company	Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
WO2002058699A1 (en) *	2001-01-25	2002-08-01	Bristol-Myers Squibb Company	Pharmaceutical forms of epothilones for oral administration
MXPA03006412A (es) *	2001-01-25	2003-10-15	Bristol Myers Squibb Co	Metodos para administrar analogos de epotilona para tratamiento de cancer.
US6893859B2 (en)	2001-02-13	2005-05-17	Kosan Biosciences, Inc.	Epothilone derivatives and methods for making and using the same
KR20040028720A (ko)	2001-02-20	2004-04-03	브리스톨-마이어스스퀴브컴파니	치료불응성 종양 치료용 에포틸론 유도체
CN1774253A (zh) *	2001-02-20	2006-05-17	布里斯托尔-迈尔斯斯奎布公司	用环氧丙酯酮衍生物治疗顽固性肿瘤
NZ527557A (en)	2001-02-27	2005-05-27	Biotechnolog Forschung Gmbh	Degradation of epothilones and ethynyl substituted epothilones
IL157443A0 (en) *	2001-03-14	2004-03-28	Bristol Myers Squibb Co	Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
MXPA03010909A (es)	2001-06-01	2004-02-17	Bristol Myers Squibb Co	Derivados de epotilona.
TWI315982B (en) *	2001-07-19	2009-10-21	Novartis Ag	Combinations comprising epothilones and pharmaceutical uses thereof
MXPA04006822A (es)	2002-01-14	2004-12-08	Novartis Ag	Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1340498A1 (de) *	2002-03-01	2003-09-03	Schering Aktiengesellschaft	Verwendung von Epothilonen zur Behandlung von mit proliferativen Prozessen assoziierten Gehirnerkrankungen
AU2003218107A1 (en) *	2002-03-12	2003-09-29	Bristol-Myers Squibb Company	C12-cyano epothilone derivatives
SI1483251T1 (sl)	2002-03-12	2010-03-31	Bristol Myers Squibb Co	C cian epotilonski derivati
TW200403994A (en)	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en) *	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2003105828A1 (en)	2002-06-14	2003-12-24	Bristol-Myers Squibb Company	Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
DE10232094A1 (de) *	2002-07-15	2004-02-05	GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF)	5-Thiaepothilone und 15-disubstituierte Epothilone
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (de)	2002-08-23	2010-05-19	Sloan-Kettering Institute For Cancer Research	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
AU2003275068B2 (en)	2002-09-23	2009-09-17	Bristol-Myers Squibb Company	Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B
CA2501610C (en) *	2002-10-11	2012-01-03	Dana-Farber Cancer Institute Inc	Epothilone derivatives for the treatment of multiple myeloma
WO2004045518A2 (en)	2002-11-15	2004-06-03	Bristol-Myers Squibb Company	Open chain prolyl urea-related modulators of androgen receptor function
US7645782B2 (en) *	2002-11-28	2010-01-12	Wolfgang Richter	Thia-epothilone derivatives for the treatment of cancer
BR0317150A (pt) *	2002-12-09	2005-11-01	Novartis Ag	Estabilizadores de microtúbulos em stents para o tratamento de estenose
GB0230024D0 (en) *	2002-12-23	2003-01-29	Novartis Ag	Organic compounds
CN100359014C (zh) *	2003-01-28	2008-01-02	北京华昊中天生物技术有限公司	一类新型埃坡霉素化合物及其制备方法和用途
WO2004071440A2 (en)	2003-02-06	2004-08-26	Bristol-Myers Squibb Company	Thiazolyl-based compounds useful as kinase inhibitors
GB0305928D0 (en) *	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
AU2008200555C1 (en) *	2003-03-14	2011-12-15	Novartis Ag	Treatment of proliferative diseases with epothilone derivatives and radiation
US7371759B2 (en)	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
DE10344882A1 (de)	2003-09-26	2005-04-21	Morphochem Ag Komb Chemie	Neue Makrocyclen zur Behandlung von Krebserkrankungen
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
WO2005054429A2 (en) *	2003-11-19	2005-06-16	The University Of Mississippi	Synthesis of the c1-c6 keto-acid synthon of the epothilones
US7420059B2 (en)	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
EP1559447A1 (de)	2004-01-30	2005-08-03	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Verwendung von Epothilonen zur Behandlung von neuronalen Konnektivitätsdefekten wie zum Beispiel Schizophrenie und Autismus
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) *	2004-05-18	2009-01-01	Franchini Miriam K	Nanoparticle dispersion containing lactam compound
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US7173031B2 (en)	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
WO2006017761A2 (en) *	2004-08-05	2006-02-16	Emory University	Epothilone analogues as therapeutic agents
EP1640004A1 (de) *	2004-09-24	2006-03-29	Schering Aktiengesellschaft	Verwendung von Epothilonen zur Behandlung von Knochenmetastasen und Knochentumoren oder Knochenkrebs
AR052142A1 (es)	2004-11-18	2007-03-07	Bristol Myers Squibb Co	Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
EP1824458A1 (de) *	2004-11-18	2007-08-29	Bristol-Myers Squibb Company	Kügelchen mit magensaftresistentem überzug mit epothilon oder einem epothilon-analogon und seine herstellung und verabreichung
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (de)	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
US7754850B2 (en)	2005-02-11	2010-07-13	University Of Southern California	Chimeric disintegrin domain
JP4954983B2 (ja)	2005-05-18	2012-06-20	ファーマサイエンス・インコーポレイテッド	Ｂｉｒドメイン結合化合物
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
JP2009532035A (ja)	2006-03-31	2009-09-10	ブリストル−マイヤーズスクイブカンパニー	微小管安定化剤に対する感受性を決定するためのバイオマーカーおよび方法
EP2029156A4 (de) *	2006-05-01	2010-07-21	Univ Southern California	Kombinationstherapie zur krebsbehandlung
CN101535300B (zh)	2006-05-16	2014-05-28	埃格拉医疗公司	Iap bir域结合化合物
JP2010511408A (ja)	2006-12-04	2010-04-15	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
JP2010518123A (ja)	2007-02-08	2010-05-27	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	癌をキュプレドキシンで予防するための組成物および方法
EP2152717A1 (de)	2007-05-25	2010-02-17	Bristol-Myers Squibb Company	Verfahren zur herstellung von epothilonverbindungen und analoga
US20090076099A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched ixabepilone
EP2065054A1 (de)	2007-11-29	2009-06-03	Bayer Schering Pharma Aktiengesellschaft	Kombinationen mit einem Prostaglandin und Verwendungen davon
EP2070521A1 (de)	2007-12-10	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Nanopartikel mit modifizierter Oberfläche
DE102007059752A1 (de)	2007-12-10	2009-06-18	Bayer Schering Pharma Aktiengesellschaft	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
JP2011509299A (ja) *	2008-01-08	2011-03-24	ブリストル−マイヤーズスクイブカンパニー	増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
MX2010011209A (es) *	2008-04-24	2010-11-12	Squibb Bristol Myers Co	Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
US8802394B2 (en)	2008-11-13	2014-08-12	Radu O. Minea	Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (de)	2009-01-27	2010-07-28	Bayer Schering Pharma Aktiengesellschaft	Stabile Polymerzusammensetzung mit einem Epothilon und einem amphiphilischen Blockpolymer
JP4500951B1 (ja) *	2009-08-07	2010-07-14	学校法人神戸学院	Ｄｎａ合成酵素阻害剤
WO2011049625A1 (en)	2009-10-20	2011-04-28	Mansour Samadpour	Method for aflatoxin screening of products
NZ599830A (en)	2009-11-05	2014-08-29	Rhizen Pharmaceuticals Sa	Novel kinase modulators
US9284350B2 (en)	2010-02-12	2016-03-15	Pharmascience Inc.	IAP BIR domain binding compounds
NZ604306A (en)	2010-05-17	2015-02-27	Incozen Therapeutics Pvt Ltd	Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US20110300150A1 (en)	2010-05-18	2011-12-08	Scott Eliasof	Compositions and methods for treatment of autoimmune and other disease
KR20130086534A (ko)	2010-06-01	2013-08-02	플러스 케미칼스, 에스.에이.	익사베필론의 고체 형태
CN101906099A (zh) *	2010-07-16	2010-12-08	泰州市今朝伟业精细化工有限公司	一种埃博霉素d-内酰胺衍生物化学合成方法
JP5889337B2 (ja)	2011-01-20	2016-03-22	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	Ｍｒｉマーカー、送達および抜取りシステムならびにこれらの製造方法および使用方法
WO2012135278A2 (en) *	2011-04-01	2012-10-04	The Research Foundation Of State University Of New York	Olefin-triggered acid amplifiers
WO2012135286A2 (en) *	2011-04-01	2012-10-04	The Research Foundation Of State University Of New York	Stabilized acid amplifiers
PH12013502240B1 (en)	2011-05-04	2018-06-27	Rhizen Pharmaceuticals Sa	Novel compounds as modulators of protein kinase
JP2014516075A (ja)	2011-06-06	2014-07-07	シェブロンフィリップスケミカルカンパニーエルピー	癌治療のためのメタロセン化合物の使用
WO2012171020A1 (en)	2011-06-10	2012-12-13	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
CN102863474A (zh)	2011-07-09	2013-01-09	陈小平	一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
WO2013008091A1 (en) *	2011-07-13	2013-01-17	Xellia Pharmaceuticals Aps	Manufacturing of epothilone derivatives and the use thereof
EP2567825B1 (de)	2011-09-12	2014-04-02	Agfa-Gevaert	Farblasermarkierungsverfahren für Sicherheitdokumentenvorläufer
CN102993239A (zh)	2011-09-19	2013-03-27	陈小平	离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
EP2793947B1 (de)	2011-12-23	2021-02-03	Innate Pharma	Enzymatische konjugation von polypeptiden
CN107082779A (zh)	2012-03-30	2017-08-22	理森制药股份公司	作为c‑met 蛋白激酶调节剂的新化合物
US10132799B2 (en)	2012-07-13	2018-11-20	Innate Pharma	Screening of conjugated antibodies
EP3564259A3 (de)	2012-11-09	2020-02-12	Innate Pharma	Kennungen für tgase-vermittelte konjugation
WO2014075391A1 (zh)	2012-11-17	2014-05-22	北京市丰硕维康技术开发有限责任公司	离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
WO2014089177A2 (en)	2012-12-04	2014-06-12	Massachusetts Institute Of Technology	Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
CA2892863C (en)	2012-12-10	2022-03-15	Mersana Therapeutics, Inc.	Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en)	2012-12-12	2014-06-19	Mersana Therapeutics,Inc.	Hydroxy-polmer-drug-protein conjugates
TWI520956B (zh)	2013-03-08	2016-02-11	台灣神隆股份有限公司	伊莎匹隆及其中間體之製備方法
US10611824B2 (en)	2013-03-15	2020-04-07	Innate Pharma	Solid phase TGase-mediated conjugation of antibodies
EP2972394A4 (de)	2013-03-15	2016-11-02	Sloan Kettering Inst Cancer	Hsp90-anzielende herzbildgebung und -therapie
TN2015000543A1 (en)	2013-06-11	2017-04-06	Bayer Pharma AG	Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
EP3010547B1 (de)	2013-06-20	2021-04-21	Innate Pharma	Enzymatische konjugation von polypeptiden
CN105517577A (zh)	2013-06-21	2016-04-20	先天制药公司	多肽的酶促偶联
ES2754397T3 (es)	2013-10-11	2020-04-17	Asana Biosciences Llc	Conjugados de proteína-polímero-fármaco
KR102087850B1 (ko)	2013-10-11	2020-03-12	메르사나 테라퓨틱스, 인코포레이티드	단백질-고분자-약물 접합체
US10341459B2 (en)	2015-09-18	2019-07-02	International Business Machines Corporation	Personalized content and services based on profile information
WO2017197045A1 (en)	2016-05-11	2017-11-16	Movassaghi Mohammad	Convergent and enantioselective total synthesis of communesin analogs
WO2018004338A1 (en)	2016-06-27	2018-01-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
US11932650B2 (en)	2017-05-11	2024-03-19	Massachusetts Institute Of Technology	Potent agelastatin derivatives as modulators for cancer invasion and metastasis
AU2018290330A1 (en)	2017-06-22	2020-01-02	Mersana Therapeutics, Inc.	Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019092148A1 (en)	2017-11-10	2019-05-16	Innate Pharma	Antibodies with functionalized glutamine residues
AU2019262520B2 (en)	2018-05-04	2025-07-10	Tagworks Pharmaceuticals B.V.	Tetrazines for high click conjugation yield in vivo and high click release yield
CA3099421C (en)	2018-05-04	2025-05-06	Tagworks Pharmaceuticals B.V.	COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY
CN113365664A (zh)	2018-10-29	2021-09-07	梅尔莎纳医疗公司	具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
US11535634B2 (en)	2019-06-05	2022-12-27	Massachusetts Institute Of Technology	Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
DK3983363T3 (da)	2019-06-17	2024-06-24	Tagworks Pharmaceuticals B V	Forbindelser til hurtig og effektiv klikfrigivelse
WO2021142202A1 (en)	2020-01-10	2021-07-15	R-Pharm Us Operating Llc	Compositions of ixabepilone
WO2022182415A1 (en)	2021-02-24	2022-09-01	Massachusetts Institute Of Technology	Himastatin derivatives, and processes of preparation thereof, and uses thereof
US20250327057A1 (en)	2021-09-06	2025-10-23	Veraxa Biotech Gmbh	Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
WO2023094525A1 (en)	2021-11-25	2023-06-01	Veraxa Biotech Gmbh	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
DK4186529T3 (da)	2021-11-25	2025-08-25	Veraxa Biotech Gmbh	Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
US20250135011A1 (en)	2021-12-08	2025-05-01	European Molecular Biology Laboratory	Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
US20250114489A1 (en)	2022-02-15	2025-04-10	Tagworks Pharmaceuticals B.V.	Masked il12 protein
CA3261603A1 (en)	2022-07-15	2024-01-18	Pheon Therapeutics Ltd	ANTIBODY-DRUG CONJUGATES
WO2024080872A1 (en)	2022-10-12	2024-04-18	Tagworks Pharmaceuticals B.V.	Strained bicyclononenes
WO2024153789A1 (en)	2023-01-20	2024-07-25	Basf Se	Stabilized biopolymer composition, their manufacture and use
WO2024191293A1 (en)	2023-03-10	2024-09-19	Tagworks Pharmaceuticals B.V.	Trans-cyclooctene with improved t-linker
KR20260046464A (ko)	2023-07-27	2026-04-07	베락사 바이오테크 게엠베하	친수성 트랜스-시클로옥텐(hyTCO) 화합물, 이를 포함하는 구조체 및 접합체
WO2025056807A1 (en)	2023-09-15	2025-03-20	Basf Se	Stabilized biopolymer composition, their manufacture and use
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025174248A1 (en)	2024-02-16	2025-08-21	Tagworks Pharmaceuticals B.V.	Trans-cyclooctenes with "or gate" release
WO2026043376A1 (en)	2024-08-22	2026-02-26	Tagworks Pharmaceuticals B.V.	Trans-cyclooctene formulations
WO2026064527A1 (en)	2024-09-19	2026-03-26	Tesseract Medicines Us, Llc	Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026064520A1 (en)	2024-09-19	2026-03-26	Tesseract Medicines Us, Llc	Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
WO2026078060A1 (en)	2024-10-08	2026-04-16	Basf Se	Tocopherol alkoxylates for biopolymer stabilization

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4272525A (en)	1978-10-23	1981-06-09	Schering Corporation	Derivatives of polyene macrolide antibiotics containing an amino sugar moiety, process for the preparation thereof, and pharmaceutical compositions containing them
IL69666A (en)	1982-09-13	1987-10-20	Lilly Co Eli	20-amino-20-deoxo-5-o-mycaminosyl-23-o-mycinosyltylonolide derivatives,their preparation and veterinary antibiotic use
US4820695A (en)	1982-09-13	1989-04-11	Eli Lilly And Company	C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
US5411947A (en)	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
JPH03101679A (ja)	1989-09-14	1991-04-26	Sankyo Co Ltd	リゾキシン誘導体
US5798345A (en)	1990-09-21	1998-08-25	Bone Care International, Inc.	Method of inhibiting the hyperproliferation of malignant cells
US5789397A (en)	1991-01-08	1998-08-04	Bone Care International, Inc.	Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
ZA923125B (en)	1991-05-02	1993-10-29	Elil Lilly And Company	Treatment of mastitis
US5217960A (en)	1991-05-03	1993-06-08	Abbott Laboratories	Erythromycin derivatives
JP3101679B2 (ja)	1991-07-02	2000-10-23	株式会社ニチレイ	動物細胞の凍結保存用血清不含培地及び保存方法
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5795882A (en)	1992-06-22	1998-08-18	Bone Care International, Inc.	Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
TW226373B (de)	1992-07-15	1994-07-11	Pfizer
EP0586738A1 (de)	1992-09-11	1994-03-16	Boehringer Ingelheim Vetmedica Gmbh	Erhöhte chemotherapeutische Zusammensetzung gegen mikrobielle Infektionen bei Fischen, enthaltend ein Benzylaminderivat und eine antimikrobielle Substanz
ZA939428B (en)	1992-12-21	1995-06-15	Lilly Co Eli	Therapeutic for gram-positive diseases of aquatic species
WO1994021657A1 (en)	1993-03-18	1994-09-29	Pfizer Inc.	Antibacterial 16-membered ring macrolides containing olefins at c-20
DE4316836A1 (de)	1993-05-19	1994-11-24	Knoell Hans Forschung Ev	Tetrahydrofuranyl-propionsäure, ein Verfahren zu ihrer Herstellung und Verwendung derselben
US5716939A (en)	1993-07-15	1998-02-10	Pfizer Inc.	Amide derivatives of 16-membered ring antibiotic macrolides
EP0639644A1 (de)	1993-08-16	1995-02-22	Ciba-Geigy Ag	Neue Makrolide und ihre Verwendung
US5763429A (en)	1993-09-10	1998-06-09	Bone Care International, Inc.	Method of treating prostatic diseases using active vitamin D analogues
WO1996009312A1 (en)	1994-09-22	1996-03-28	Pfizer Inc.	Antibiotic macrolides
WO1996011398A1 (en)	1994-10-07	1996-04-18	Merck & Co., Inc.	Process for assessing tubulin protein polymerization
IL117200A0 (en)	1995-02-21	1996-06-18	Schering Ag	Diethylenetriamine-pentaacetic acid monoamide derivatives pharmaceutical compostions containing the same and processes for the preparation thereof
US6124453A (en)	1995-07-04	2000-09-26	Novartis Ag	Macrolides
US5515936A (en) *	1995-07-10	1996-05-14	Vehicules Ts Bellechasse Ltee	Track tensioning system for endless track propelled vehicle
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
JP4183099B2 (ja)	1995-11-17	2008-11-19	ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ）	エポチロンｃおよびｄ、製造法ならびに組成物
DE19542986A1 (de)	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
WO1997019088A1 (en)	1995-11-21	1997-05-29	Hoechst Celanese Corporation	Novel nonlinear optical molecules and polymers incorporating them
EP0778283A3 (de)	1995-12-05	1998-01-28	Pfizer Inc.	Antibiotische Makrolide
DE19636343C1 (de)	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
AU716610B2 (en)	1996-08-30	2000-03-02	Novartis Ag	Method for producing epothilones, and intermediate products obtained during the production process
GB9623944D0 (en)	1996-11-15	1997-01-08	Zeneca Ltd	Bicyclic amine derivatives
ES2312695T3 (es)	1996-11-18	2009-03-01	Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf)	Epotilones e y f.
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en)	1996-12-03	2012-09-18	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
AT404477B (de)	1997-01-15	1998-11-25	Thal Hermann Dipl Ing	Gebündeltes spannglied und verfahren zur herstellung desselben
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
JP2001513098A (ja)	1997-02-25	2001-08-28	ゲゼルシャフトフュアバイオテクノロギッシェフォーシュンクエムベーハー（ゲーベーエフ）	側鎖を修飾したエポチロン
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja)	1997-04-18	2008-03-26	ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6384230B1 (en)	1997-07-16	2002-05-07	Schering Aktiengesellschaft	Thiazole derivatives, method for their production and use
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
TR200002299T2 (tr)	1998-02-05	2000-11-21	Novartis Ag	Epotilon kompozisyonları.
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2322157C (en)	1998-02-25	2012-05-29	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6136630A (en) *	1998-06-04	2000-10-24	The Regents Of The University Of Michigan	Method of making a micromechanical device from a single crystal semiconductor substrate and monolithic sensor formed thereby
WO2000000485A1 (de)	1998-06-30	2000-01-06	Schering Aktiengesellschaft	Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
WO2000031247A2 (en)	1998-11-20	2000-06-02	Kosan Biosciences, Inc.	Recombinant methods and materials for producing epothilone and epothilone derivatives
PT1140944E (pt) *	1998-12-22	2004-01-30	Novartis Pharma Gmbh	Derivados de epotilona e sua utilizacao como agentes antitumorais
MXPA01008328A (es)	1999-02-18	2002-06-04	Schering Ag	Derivados de 18 -haluro epotilona, metodo para su produccion y su uso farmaceutico.
US6211412B1 (en)	1999-03-29	2001-04-03	The University Of Kansas	Synthesis of epothilones
US7125893B1 (en)	1999-04-30	2006-10-24	Schering Ag	6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
PE20010116A1 (es)	1999-04-30	2001-02-15	Schering Ag	Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
UA75365C2 (en)	2000-08-16	2006-04-17	Bristol Myers Squibb Co	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EE200300323A (et)	2001-01-25	2003-10-15	Bristol-Myers Squibb Company	Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
ES2304240T3 (es)	2001-01-25	2008-10-01	Bristol-Myers Squibb Company	Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
WO2002058699A1 (en)	2001-01-25	2002-08-01	Bristol-Myers Squibb Company	Pharmaceutical forms of epothilones for oral administration
CN1774253A (zh)	2001-02-20	2006-05-17	布里斯托尔-迈尔斯斯奎布公司	用环氧丙酯酮衍生物治疗顽固性肿瘤
IL157443A0 (en)	2001-03-14	2004-03-28	Bristol Myers Squibb Co	Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
US7026362B2 (en)	2001-10-09	2006-04-11	Simax Technologies, Inc.	Sol-gel process utilizing reduced mixing temperatures

1998
- 1998-05-26 US US09/084,542 patent/US6605599B1/en not_active Ceased
- 1998-06-16 EE EEP200000013A patent/EE04566B1/xx not_active IP Right Cessation
- 1998-06-16 DE DE69840693T patent/DE69840693D1/de not_active Expired - Lifetime
- 1998-06-16 CA CA002296012A patent/CA2296012C/en not_active Expired - Lifetime
- 1998-06-16 DE DE69832294T patent/DE69832294T2/de not_active Expired - Lifetime
- 1998-06-16 NZ NZ501198A patent/NZ501198A/en not_active IP Right Cessation
- 1998-06-16 EP EP04028581A patent/EP1531153A1/de not_active Withdrawn
- 1998-06-16 EP EP98930300A patent/EP1019389B1/de not_active Expired - Lifetime
- 1998-06-16 TR TR2000/00065T patent/TR200000065T2/xx unknown
- 1998-06-16 ES ES04021059T patent/ES2322807T3/es not_active Expired - Lifetime
- 1998-06-16 BR BRPI9810555A patent/BRPI9810555A8/pt active Search and Examination
- 1998-06-16 WO PCT/US1998/012550 patent/WO1999002514A2/en not_active Ceased
- 1998-06-16 AT AT04021059T patent/ATE426598T1/de not_active IP Right Cessation
- 1998-06-16 CN CNB988069067A patent/CN100384834C/zh not_active Expired - Fee Related
- 1998-06-16 IL IL13361398A patent/IL133613A/xx not_active IP Right Cessation
- 1998-06-16 HU HU0103111A patent/HU227444B1/hu not_active IP Right Cessation
- 1998-06-16 CZ CZ20000058A patent/CZ297904B6/cs not_active IP Right Cessation
- 1998-06-16 ID IDW20000002A patent/ID23771A/id unknown
- 1998-06-16 EP EP04028580A patent/EP1526133A1/de not_active Withdrawn
- 1998-06-16 RO RO99-01332A patent/RO120340B1/ro unknown
- 1998-06-16 EP EP04021059A patent/EP1493738B1/de not_active Expired - Lifetime
- 1998-06-16 AT AT98930300T patent/ATE309236T1/de active
- 1998-06-16 ES ES98930300T patent/ES2251088T3/es not_active Expired - Lifetime
- 1998-06-16 KR KR1020007000120A patent/KR100569041B1/ko not_active Expired - Lifetime
- 1998-06-16 GE GEAP19985171A patent/GEP20032897B/en unknown
- 1998-06-16 AU AU79720/98A patent/AU731497B2/en not_active Ceased
- 1998-06-16 DK DK98930300T patent/DK1019389T3/da active
- 1998-06-16 JP JP50867399A patent/JP4090514B2/ja not_active Expired - Fee Related
- 1998-06-16 PL PL338003A patent/PL197404B1/pl unknown
- 1998-07-02 TW TW087110722A patent/TW562802B/zh not_active IP Right Cessation
- 1998-07-07 CO CO98038387A patent/CO4940501A1/es unknown
- 1998-07-07 EG EG79298A patent/EG24464A/xx active
- 1998-07-07 PE PE1998000604A patent/PE104599A1/es not_active Application Discontinuation
- 1998-07-08 AR ARP980103322A patent/AR013358A1/es active IP Right Grant
- 1998-07-08 MY MYPI98003121A patent/MY124151A/en unknown
2000
- 2000-01-07 NO NO20000076A patent/NO322494B1/no not_active IP Right Cessation
- 2000-01-10 BG BG104068A patent/BG64952B1/bg unknown
- 2000-02-02 LV LVP-00-17A patent/LV12569B/en unknown
2003
- 2003-04-03 US US10/405,886 patent/US7125899B2/en not_active Expired - Lifetime
2006
- 2006-08-30 US US11/512,623 patent/US7241755B2/en not_active Expired - Lifetime
2007
- 2007-06-13 JP JP2007156260A patent/JP4885067B2/ja not_active Expired - Fee Related
- 2007-06-15 US US11/763,636 patent/US8536327B2/en not_active Expired - Fee Related
2009
- 2009-08-11 US US12/539,498 patent/USRE41893E1/en not_active Expired - Lifetime
- 2009-08-11 US US12/539,496 patent/USRE41895E1/en not_active Expired - Lifetime
- 2009-08-11 US US12/539,492 patent/USRE41911E1/en not_active Expired - Lifetime
2010
- 2010-09-15 US US12/882,769 patent/USRE43003E1/en not_active Expired - Fee Related
2013
- 2013-08-14 US US13/966,613 patent/US8921542B2/en not_active Expired - Fee Related
2014
- 2014-11-25 US US14/553,081 patent/US20150080440A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20000076D0 (no)	2000-01-07
US20030220295A1 (en)	2003-11-27
KR20010021562A (ko)	2001-03-15
US20130331564A1 (en)	2013-12-12
AU731497B2 (en)	2001-03-29
EP1531153A1 (de)	2005-05-18
BR9810555A (pt)	2000-08-15
USRE41895E1 (en)	2010-10-26
US8536327B2 (en)	2013-09-17
PL197404B1 (pl)	2008-03-31
USRE43003E1 (en)	2011-12-06
CZ200058A3 (cs)	2001-01-17
DK1019389T3 (da)	2006-01-16
JP4090514B2 (ja)	2008-05-28
IL133613A0 (en)	2001-04-30
CZ297904B6 (cs)	2007-04-25
HUP0103111A3 (en)	2003-01-28
BG104068A (en)	2000-09-29
DE69832294D1 (de)	2005-12-15
PL338003A1 (en)	2000-09-25
US7125899B2 (en)	2006-10-24
US20150080440A1 (en)	2015-03-19
DE69840693D1 (de)	2009-05-07
JP2007291121A (ja)	2007-11-08
JP4885067B2 (ja)	2012-02-29
EP1019389B1 (de)	2005-11-09
USRE41911E1 (en)	2010-11-02
EP1019389A2 (de)	2000-07-19
JP2002512634A (ja)	2002-04-23
EP1493738A1 (de)	2005-01-05
WO1999002514A3 (en)	2001-05-10
US8921542B2 (en)	2014-12-30
PE104599A1 (es)	2000-01-19
EE200000013A (et)	2000-08-15
NO322494B1 (no)	2006-10-16
ATE426598T1 (de)	2009-04-15
GEP20032897B (en)	2003-02-25
TR200000065T2 (tr)	2000-11-21
ES2322807T3 (es)	2009-06-29
EE04566B1 (et)	2005-12-15
CO4940501A1 (es)	2000-07-24
EG24464A (en)	2009-07-16
ID23771A (id)	2000-05-11
AU7972098A (en)	1999-02-08
HK1031731A1 (zh)	2001-06-22
US20070255055A1 (en)	2007-11-01
CA2296012A1 (en)	1999-01-21
KR100569041B1 (ko)	2006-04-10
LV12569A (en)	2000-11-20
RO120340B1 (ro)	2005-12-30
CN100384834C (zh)	2008-04-30
EP1019389A4 (de)	2001-11-07
BG64952B1 (bg)	2006-10-31
US7241755B2 (en)	2007-07-10
NO20000076L (no)	2000-01-07
HU227444B1 (en)	2011-06-28
IL133613A (en)	2005-11-20
ES2251088T3 (es)	2006-04-16
HUP0103111A2 (hu)	2002-04-29
EP1493738B1 (de)	2009-03-25
AR013358A1 (es)	2000-12-27
LV12569B (en)	2001-04-20
MY124151A (en)	2006-06-30
US6605599B1 (en)	2003-08-12
US20060287371A1 (en)	2006-12-21
CN1270589A (zh)	2000-10-18
TW562802B (en)	2003-11-21
CA2296012C (en)	2008-10-21
DE69832294T2 (de)	2006-05-24
BRPI9810555A8 (pt)	2017-09-19
USRE41893E1 (en)	2010-10-26
HK1026905A1 (en)	2000-12-29
NZ501198A (en)	2001-09-28
EP1526133A1 (de)	2005-04-27
WO1999002514A2 (en)	1999-01-21

Legal Events

Date

Code

Title

Description

2006-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1019389

Country of ref document: EP

Publication	Publication Date	Title
ATE309236T1 (de)	2005-11-15	Epothilonderivate
DK1005446T3 (da)	2004-06-07	N-aroylphenylalaninderivater
ATE235220T1 (de)	2003-04-15	Resorcinderivate
ID22781A (id)	1999-12-09	Turunan-turunan nikotinamida
DE69817186D1 (de)	2003-09-18	Diaminorhodamin-derivate
NO20010193D0 (no)	2001-01-12	Tiobenzimidazol-derivater
ATE236136T1 (de)	2003-04-15	Benzosulfonderivate
PT915088E (pt)	2003-01-31	Derivados de d-prolina
NO20010514L (no)	2001-01-30	Aminometylkarboksylsyre-derivater
ATE259810T1 (de)	2004-03-15	Phenyl-xanthinderivate
ATE255098T1 (de)	2003-12-15	Substituierte chromanderivate
PT1003719E (pt)	2002-10-31	Derivados microbicidas de n-sulfonil-glicinalquiniloxifenemetilamida
ATE440854T1 (de)	2009-09-15	5-deoxy-cytidin-derivate
PT1027362E (pt)	2005-08-31	Derivados de cetolidos 2-halogeno-6-o-substituidos
ATE255099T1 (de)	2003-12-15	Substituierte chromanderivate
DK1115716T3 (da)	2003-02-24	2-phenylpyran-4-on-derivater
DK0966437T3 (da)	2002-10-07	5-Aroylnaphthalenderivater
ATE233253T1 (de)	2003-03-15	Chromanderivate
DK1134219T3 (da)	2005-10-17	Cucloalkylsubstituerede aminomethylpyrrolidinderivater
DE69829682D1 (de)	2005-05-12	Cis-disubstituierte aminocycloalkyl-pyrrolidin-derivate
DE69828780D1 (de)	2005-03-03	Amidinocamptpthecin-derivate
NO981495D0 (no)	1998-04-02	Phenoxymetylpiperidin-derivater
DK1060183T3 (da)	2003-08-11	5-deoxycytidinderivater
ATE372989T1 (de)	2007-09-15	Azolinderivate
DK1015447T3 (da)	2002-06-17	Piperidinylmethyloxazolidinonderivat